Normo~CAT: Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
Sponsor
Sanofi (Industry)
Overall Status
Completed
CT.gov ID
NCT00501566
Collaborator
(none)
148
12
9
12.3
1.4
Study Details
Study Description
Brief Summary
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.
The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
148 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study
Study Start Date
:
Apr 1, 2004
Actual Study Completion Date
:
Jan 1, 2005
Outcome Measures
Primary Outcome Measures
- Change in body weight [within 14 days]
Secondary Outcome Measures
- Abdominal girth and discomfort [14 days]
- Paracentesis [14 days]
- Quality of life [14 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence
-
Moderate or tense ascites
-
Serum sodium of >130 mmol/l.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sanofi-Aventis Administrative Office | Buenos Aires | Argentina | ||
2 | Sanofi-Aventis Administrative Office | Cove | New South Wales | Australia | |
3 | Sanofi-Aventis Administrative Office | Diegem | Belgium | ||
4 | Sanofi-Aventis Administrative Office | Laval | Quebec | Canada | |
5 | Sanofi-Aventis Administrative Office | Zagreb | Croatia | ||
6 | Sanofi-Aventis Administrative Office | Praha | Czech Republic | ||
7 | Sanofi-Aventis Administrative Office | Paris | France | ||
8 | Sanofi-Aventis Administrative Office | Berlin | Germany | ||
9 | Sanofi-Aventis Administrative Office | Budapest | Hungary | ||
10 | Sanofi-Aventis Administrative Office | Milan | Italy | ||
11 | Sanofi-Aventis Administrative Office | Bucuresti | Romania | ||
12 | Sanofi-Aventis Administrative Office | Barcelona | Spain |
Sponsors and Collaborators
- Sanofi
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00501566
Other Study ID Numbers:
- DFI5563
- SR121463
First Posted:
Jul 16, 2007
Last Update Posted:
Jul 16, 2007
Last Verified:
Jul 1, 2007
Keywords provided by ,
,
Additional relevant MeSH terms: